ES2170747T3 - Analogos superiores de trombomodulina para uso farmaceutico. - Google Patents

Analogos superiores de trombomodulina para uso farmaceutico.

Info

Publication number
ES2170747T3
ES2170747T3 ES91918117T ES91918117T ES2170747T3 ES 2170747 T3 ES2170747 T3 ES 2170747T3 ES 91918117 T ES91918117 T ES 91918117T ES 91918117 T ES91918117 T ES 91918117T ES 2170747 T3 ES2170747 T3 ES 2170747T3
Authority
ES
Spain
Prior art keywords
thrombin
analogs
superior
pharmaceutical use
methods
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES91918117T
Other languages
English (en)
Inventor
Charles B Glaser
Michael John Morser
David Richard Light
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Paion Deutschland GmbH
Original Assignee
Paion GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Paion GmbH filed Critical Paion GmbH
Application granted granted Critical
Publication of ES2170747T3 publication Critical patent/ES2170747T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/745—Blood coagulation or fibrinolysis factors
    • C07K14/7455—Thrombomodulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Hematology (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Zoology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Toxicology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

LA INVENCION SE REFIERE AL USO DE ANALOGOS DE LA TROMBOMODULINA (TM) QUE TIENEN CAPACIDAD DE MEJORAR LA ACTIVACION MEDIATIZADA DE LA TROMBINA DE LA PROTEINA C PERO QUE TIENEN UNA CAPACIDAD SUBSTANCIALMENTE REDUCIDA PARA INHIBIR LAS ACTIVIDADES PROCOAGULANTES DIRECTAS DE LA TROMBINA, TALES COMO, POR EJEMPLO, LA CONVERSION MEDIATIZADA DE LA TROMBINA DEL FIBRINOGENO EN FIBRINA. ESTOS ANALOGOS, SON UTILES, POR EJEMPLO, EN LA TERAPIA ANTITROMBOTICA. SE HAN DESCUBIERTO NUEVAS PROTEINAS, SECUENCIAS DE GENES DE ACIDO NUCLEICO, SUSTANCIAS FARMACEUTICAS Y METODOS PARA INHIBIR LA ACTIVIDAD TROMBOTICA. SE INCLUYEN METODOS PARA INCREMENTAR LA VIDA MEDIA DE CIRCULACION DE LAS PROTEINAS.
ES91918117T 1990-08-15 1991-08-15 Analogos superiores de trombomodulina para uso farmaceutico. Expired - Lifetime ES2170747T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US56845690A 1990-08-15 1990-08-15

Publications (1)

Publication Number Publication Date
ES2170747T3 true ES2170747T3 (es) 2002-08-16

Family

ID=24271371

Family Applications (1)

Application Number Title Priority Date Filing Date
ES91918117T Expired - Lifetime ES2170747T3 (es) 1990-08-15 1991-08-15 Analogos superiores de trombomodulina para uso farmaceutico.

Country Status (8)

Country Link
EP (1) EP0544826B1 (es)
AT (1) ATE211390T1 (es)
AU (2) AU8723391A (es)
CA (2) CA2087271C (es)
DE (1) DE69132889T2 (es)
DK (1) DK0544826T3 (es)
ES (1) ES2170747T3 (es)
WO (1) WO1992003149A1 (es)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6063763A (en) * 1989-04-28 2000-05-16 Schering Aktiengesellschaft Protease-resistant thrombomodulin analogs
FR2689640B1 (fr) * 1992-04-06 1997-08-08 Bio Merieux Procede pour la determination d'une activite proteine c et/ou proteine s dans un echantillon plasmatique.
US6500646B1 (en) 1996-12-27 2002-12-31 Mochida Pharmaceutical Co., Ltd. Cell membrane-directed drugs
DE19749197A1 (de) * 1997-11-07 1999-05-12 Dade Behring Marburg Gmbh Verfahren zur Bestimmung des antikoagulatorischen Potentials einer Probe
CA2502539A1 (en) * 2002-10-17 2004-04-29 Pharming Intellectual Property B.V. Protein modification
US7553930B2 (en) 2003-01-06 2009-06-30 Xencor, Inc. BAFF variants and methods thereof
BRPI0720158A2 (pt) 2006-10-06 2014-05-20 Asahi Kasei Pharma Corp Agentes para terapia e/ou melhora de coagulação intravascular disseminada, para reduzir a probabilidade de morte em pacientes sofrendo da mesma, métodos para selecionar pacientes, e, para tratar e/ou melhorar coagulação intravascular disseminada
TW201431872A (zh) 2007-03-23 2014-08-16 Asahi Kasei Pharma Corp 高純度可溶性凝血酶調節素之製造方法
EP2120049A1 (de) 2008-05-14 2009-11-18 PAION Deutschland GmbH Lösliches Thrombomodulin als Biomarker bei Therapien mit Gerinnungshemmern
AU2009347614A1 (en) 2009-06-12 2012-01-19 Paion Deutschland Gmbh Treatment of coagulopathy with hyperfibrinolysis
AU2011246021B2 (en) 2010-04-30 2014-03-13 Asahi Kasei Pharma Corporation High-purity soluble thrombomodulin and method for producing same
CN103037893A (zh) 2010-06-14 2013-04-10 帕昂德国有限公司 具有纤溶亢进的凝血病的治疗
US9592275B2 (en) 2011-11-15 2017-03-14 Asahi Kasei Pharma Corporation Medicament for therapeutic treatment and/or improvement of sepsis
CA3116686A1 (en) 2018-10-22 2020-04-30 Asahi Kasei Pharma Corporation Medicament for therapeutic treatment and/or improvement of sepsis accompanied by coagulopathy

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4912207A (en) * 1987-05-06 1990-03-27 Washington University DNA clone of human thrombomodulin and portions thereof
DK299087D0 (da) * 1987-06-12 1987-06-12 Novo Industri As Proteins and derivatives thereof
AU646633B2 (en) * 1989-02-17 1994-03-03 Codon Soluble analogs of thrombomodulin
US5256770A (en) * 1990-04-09 1993-10-26 Schering Ag Oxidation resistant thrombomodulin analogs

Also Published As

Publication number Publication date
DK0544826T3 (da) 2002-04-22
WO1992003149A1 (en) 1992-03-05
EP0544826B1 (en) 2002-01-02
DE69132889T2 (de) 2002-08-29
AU692988B2 (en) 1998-06-18
CA2087271A1 (en) 1992-02-16
DE69132889D1 (de) 2002-02-07
CA2648350A1 (en) 1992-03-05
EP0544826A1 (en) 1993-06-09
ATE211390T1 (de) 2002-01-15
EP0544826A4 (es) 1994-04-27
CA2087271C (en) 2009-03-24
AU4554396A (en) 1996-04-26
AU8723391A (en) 1992-03-17

Similar Documents

Publication Publication Date Title
RU95115239A (ru) Аналог эритропоэтина
ES2170747T3 (es) Analogos superiores de trombomodulina para uso farmaceutico.
ES557116A0 (es) Procedimiento para la obtencion de compuestos de desulfatohirudina
DE68929043D1 (de) Für androgen-rezeptor-protein kodierende dna
AU9315398A (en) Chemokine peptides, variants, derivatives and analogs. their use in methods to inhibit or augment an inflammatory response
YU8997A (sh) Prečišćen protein koji ima serinsku proteaznu inhibitorsku aktivnost i farmaceutski preparat koji ga sadrži
DK0409472T3 (da) Knoglemorfogenetisk protein
DK0910647T3 (da) Human DNase i hyperaktive varianter
DE3854952D1 (de) Mykobakterielle rekombinanten und peptide
MY101972A (en) Primate interleukin - 4
ATE264913T1 (de) Protease-resistente analoge des thrombomodulin
JPS6485096A (en) Hybrid human protein c and biotechnological synthesis thereof
DE69333346D1 (de) Neuartiges p- selectin ligandenprotein
CA2170515A1 (en) Nucleotide sequences for novel protein tyrosine phosphatases
NZ503235A (en) Amino-terminally truncated RANTES as chemokine antagonists
DE69334146D1 (de) Peptide mit gdp-austauschfaktorartiger wirkung, dafür kodierende nukleinsäuresequenzen, ihre herstellung und verwendung
PT84089A (en) Dna sequences coding for proteins having the biological activity of husi-type i inhibitors biotechnological methods for the preparation of said proteins and pharmaceutical compositions containing said proteins
ES2171563T3 (es) Nueva familia de inhibidores de proteasas, y otras sustancias de actividad biologica.
DK102787D0 (da) Isohexidnucleosider og farmaceutiske praeparater indeholdende disse
ATE278011T1 (de) Human dnase ii
ES2059801T3 (es) Nuevas linfoquinas, secuencias de adn que codifican para estas linfoquinas, y composiciones farmaceuticas conteniendo estas linfoquinas.
Glaser et al. Superior thrombomodulin analogs for pharmaceutical use

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 544826

Country of ref document: ES